Background and Aims

Dynamic contrast-enhanced EUS (CE-EUS) for quantification of perfusion in colonic tumors has not previously been reported in the literature. The aim of this study was to investigate correlations between perfusion parameters and vessel density assessed by immunohistochemical staining with antibodies toward CD31 and CD105.

Methods

We conducted a prospective clinical study of 28 patients with left-sided colonic adenocarcinoma who underwent CE-EUS and left-sided hemicolectomy within 2 weeks. CE-EUS recordings were analyzed in 2 regions of interest: the entire tumor and the most enhanced area. Immunohistochemical staining with CD31 and CD105 was performed on tumor tissue sections. The slides were manually scanned for highly vascularized areas, and counting of vessels was performed in hotspots within the tumor and invasive front. New vasculature was assessed by CD105. Associations between CE-EUS and CD31 and CD105 were investigated using Spearman correlation.

Results

We found significant P values for the correlation between CD31 and rise time (rho = .603 [95% confidence interval (95% CI), .238-.816]; P = .001) in tumor tissue and for the correlation between CD31 and rise time (rho = .50 [95% CI, .201-.695]; P = .008) and fall time (rho = .52 [95% CI, .204-.723]; P = .006) corresponding to the invasive front. We found no correlations between perfusion values evaluated by CE-EUS and CD105.

Conclusions

Our results show a significant correlation for vessel density evaluated by CD31 and perfusion parameters evaluated by CE-EUS. This may be the first step toward using real-time CE-EUS for monitoring antiangiogenic therapies in colonic cancer. (Clinical trial registration number: NCT02324023.)

中文翻译：

---

动态对比增强EUS用于结肠癌肿瘤灌注定量研究：一项前瞻性队列研究

背景和目标

先前尚未在文献中报道过动态对比增强EUS（CE-EUS）用于量化结肠肿瘤中的灌注。这项研究的目的是研究通过针对CD31和CD105的抗体进行免疫组织化学染色评估的灌注参数与血管密度之间的相关性。

方法

我们进行了一项前瞻性临床研究，对28例行CE-EUS并在2周内进行左侧半结肠切除术的左侧结肠腺癌患者进行了研究。CE-EUS记录在两个感兴趣的区域中进行了分析：整个肿瘤和增强最大的区域。在肿瘤组织切片上用CD31和CD105进行免疫组织化学染色。手动扫描载玻片上高度血管化的区域，并在肿瘤和浸润前线内的热点进行血管计数。通过CD105评估新的脉管系统。使用Spearman相关性研究了CE-EUS与CD31和CD105之间的关联。

结果

我们发现 肿瘤组织中CD31与上升时间之间的相关性具有显着的P值（rho = .603 [95％置信区间（95％CI），. 238-.816]；P = .001）以及CD31之间的相关性和上升时间（RHO = 0.50 [95％CI，0.201-0.695]; P  = 0.008）和下降时间（RHO = 0.52 [95％CI，0.204-0.723]; P  = 0.006）对应于侵入性前沿。我们发现CE-EUS和CD105评估的灌注值之间没有相关性。

结论

我们的结果表明，通过CD31评估的血管密度与通过CE-EUS评估的灌注参数具有显着相关性。这可能是使用实时CE-EUS监测结肠癌抗血管生成疗法的第一步。（临床试验注册号：NCT02324023。）